Meet Our Interns!
We are so excited to welcome our 8 new interns for our 2022 internship program – learn a little bit more about each the newest additions to COTA.
Advance with clarity
When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.
Our Approach
COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.
We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.
Our Value
Inform
Market of current oncologics and decisions to drive future therapeutic areas.
Read Customer Case Study:
Accelerate
Drug development and build real-world comparator arms.
Read Customer Case Study:
Our Difference
Data Source
- Records sourced from tertiary referral centers capture complex and advanced cancers with rigorous EMR documentation and genomic profiling capabilities.
Abstraction
- Technology enabled human abstraction allows for nuances in unstructured data to be captured manually by medical professionals.
Flexibility
- Solution-oriented agility enables rapid assessment and implementation of augmentation requests.
Curation Depth
- COTA’s standard-level dataset goes deeper than traditional sources, capturing the clinical information that is most valuable to life sciences.
Our Products
*Complexity based on ability to define, curate, and deliver; can include additional biomarkers, labs, imaging, pathology, and more.
Getting Focused
COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.
COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.
Life sciences companies have used our data to support HEOR, commercial assessments, and clinical development, including supplementing clinical trial data with RWD in the form of external comparator controls. We are open to discussing any other opportunities, as well as your data needs and how COTA can generate value for your organization.
We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.
Our collaborative and flexible approach enables us to succeed with emerging biopharma partners. We work alongside EBPs to provide analytical, medical, and strategic support to validate use of COTA data towards EBP goals.
Latest Resources
COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022
COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
Enterprise Data Strategies for Life Sciences with Datavant’s Su Huang
In this episode of Real World Talk we welcome Su Huang, the Head of Data Strategy at Datavant. Su shares real-world experiences implementing enterprise data strategies and the efficiencies that can be gained when teams across an organization are involved in the process.
Interested in learning more about how we can transform cancer care together?
